Unique ID issued by UMIN | UMIN000012788 |
---|---|
Receipt number | R000014933 |
Scientific Title | A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer |
Date of disclosure of the study information | 2014/01/14 |
Last modified on | 2015/05/26 14:24:41 |
A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin
in Chemotherapy-Naive Patients with
Advanced Non-Small-Cell Lung Cancer
A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin
in Chemotherapy-Naive Patients with
Advanced Non-Small-Cell Lung Cancer
A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin
in Chemotherapy-Naive Patients with
Advanced Non-Small-Cell Lung Cancer
A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin
in Chemotherapy-Naive Patients with
Advanced Non-Small-Cell Lung Cancer
Japan |
previously untreated advanced non-small cell lung cancer
Pneumology | Hematology and clinical oncology |
Malignancy
NO
To determine the recommended dose of chemotherapy with carboplatin plus weekly nab-paclitaxel in patients with previously untreated advanced non-small cell lung cancer
Safety
Phase I
determine the recommended dose
Safety, Efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
nab-paclitaxel weekly for 3 of 4 weeks (3-weekly) with carboplatin on day 1 of each 4-week cycle
20 | years-old | <= |
Not applicable |
Male and Female
1) Cytologically or histologically documented non-small cell carcinoma of the lung.
2)previously untreated recurrence with distant metastasis after surgery, or previously untreated clinical stage IV or IIIB (including only patients with no indications for curative radiotherapy)
3) age older thean 20years at the time of registration
4) Have Eastern Cooperative Oncology Group performance status (PS) of 0 or 1
5) Have measurable lesions (RECIST version1.1)
6) Have adequate organ function within 14 days before study entry
leucocytes >3000/mm3
neutrophils>1,500/mm3
platelets >100,000/mm3
hemoglobin > 9g/dl],
adequate hepatic function
adequate renal function
partial pressure of arterial oxygen>60Torr or Peripheral capillary oxygen saturation>90%
8) Have signed an informed consent document
1)History of radiotherapy for a primary lesion
2)Superior vena cava syndrome
3)Hisstory of severe drug allergy
4)With massive or uncontrolled pleural effusion
5)With massive or uncontrolled pericardial effusionor ascites
6)With active infection
7)interstitial pneumoia/active lung fibrosis on chest x-ray
8)With symptomatic brain metastasis
9)active concomitant malignancy
10)Uncontrolled psychiatric disease
11)Peripheral sensory or motor neuropathy severe than Grade 2(by CTCAE ver4.0)
12)Others judged by attending physician
30
1st name | |
Middle name | |
Last name | Masataka Hirabayashi |
Hyogo Prefectural Amagasaki Hospital
Department of Respiratory Medicine
1-1-1, Higashidaimotsucho, Amagasaki-shi, Hyogo, 660-0828, Japan
06-6482-1521
Masataka_Hirabayashi@pref.hyogo.lg.jp
1st name | |
Middle name | |
Last name | Katsuya Hirano |
Hyogo Prefectural Amagasaki Hospital
Department of Respiratory Medicine
1-1-1, Higashidaimotsucho, Amagasaki-shi, Hyogo, 660-0828, Japan
06-6482-1521
khirano1979@gmail.com
Department of Respiratory Medicine in Hyogo Prefectural Amagasaki Hospital
none
Self funding
NO
兵庫県立尼崎病院
2014 | Year | 01 | Month | 14 | Day |
Partially published
Main results already published
2013 | Year | 12 | Month | 13 | Day |
2014 | Year | 01 | Month | 14 | Day |
2014 | Year | 01 | Month | 08 | Day |
2015 | Year | 05 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014933